Collapsin Response-Mediator Protein-5 (CRMP-5) Neuronal IgG Titer, Serum
Use
CRMP-5-IgG is a useful marker for evaluating neurological autoimmunity, particularly those associated with small-cell lung carcinoma and thymoma. This test aids in reporting an end titer result from serum specimens and provides key insights into neurological disorders by identifying CRMP-5 neuronal IgG. Its presence predicts the likelihood of small-cell lung carcinoma or thymoma with a 75% to 80% certainty, depending on antibody detection.
Special Instructions
Only orderable as a reflex following specific immunofluorescence pattern suggestions. It is crucial that handling, storage, and transportation of specimens follow outlined stability conditions to ensure test accuracy. Use the Mayo Clinic Laboratories for additional evaluations if other paraneoplastic syndromes are suspected.
Limitations
CRMP-5-IgG is not detected if serum titer is low (<1:120) or if coexisting antibodies are present. It cannot be used as a sole screening tool for neurological autoimmunity, and seronegativity does not exclude the presence of a neoplasm. Interfering substances can be a cause of false negatives, which require absorption techniques for correction. Critical values can fail if specimen collection and handling aren't done according to specified guidelines.
New York Approved
Methodology
Immunoassay (Indirect Immunofluorescence Assay (IFA))
Biomarkers
LOINC Codes
- 94815-8
- 94815-8
Result Turnaround Time
5-8 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
Not provided
Minimum Volume
0.6 mL
Causes for Rejection
Gross hemolysis, gross lipemia, gross icterus
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 28 days |
| Frozen | 28 days |